SCHEMBL3013584

SCHEMBL3013584

CCOc1ccc(-c2csc(N3CCC(S(=O)(=O)c4cccc(Br)c4)CC3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
LMNA P02545 4/20 0.45
MAPK1 P28482 3/20 0.45
RAB9A P51151 10/20 0.44
SMN1; SMN2 Q16637 8/20 0.44
NPC1 O15118 8/20 0.44
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
CDC25A P30304 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011289 0.90 MAPT (0.56) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3009872 0.90 MAPT (0.47) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3019586 0.90 RAB9A (0.48) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3007794 0.89 SMN1; SMN2 (0.52) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3011197 0.88 KMT2A (0.47) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3016854 0.87 KCNQ1 (0.47) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3018530 0.87 SMN1; SMN2 (0.53) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3009647 0.87 KMT2A (0.45) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3018761 0.86 KMT2A (0.46) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3017067 0.86 RORC (0.37) MAPTMEN1KMT2ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.